Premium
Transfusions in the Treatment of Hemorrhagic Diseases
Author(s) -
Quick Armand J.,
Greenwalt Tibor J.,
Hussey Clara V.
Publication year - 1961
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.1961.tb00020.x
Subject(s) - medicine , fresh frozen plasma , hypoprothrombinemia , coagulation , blood transfusion , whole blood , heparin , prothrombin time , transfusion therapy , platelet , surgery , anesthesia , vitamin k
The transfusion of fresh or fresh frozen plasma serves as a specific means to correct in part and temporarily the coagulation defect in hemophilia A, hemophilia B, hereditary hypoprothrombinemia vera, and congenital deficiencies of labile, stable and Stuart‐Prower factors (factors V, VII and X). The effect of a transfusion can usually be measured by simple tests such as the prothrombin time and the prothrombin consumption time. To correct thrombocytopenia by transfusion, platelet‐rich plasma should be given. Whole blood should only be used when the bleeding is massive and continuous or if the hemoglobin is very low. Transfusion of either whole blood or plasma into patients who have congenital or acquired anticoagulants in the blood, such as heparin or antithromboplastinogen (AHG or factor VIII), is ineffective and is likely to accentuate particularly the latter condition.